> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# All 50 States Apply for Medicaid International Drug Pricing
- URL: https://www.theamericanquorum.com/all-50-states-apply-for-medicaid-international-drug-pricing/
- Published: 2026-09-19T04:52:01.000Z
- Updated: 2026-09-19T04:52:01.000Z
- Description: All 50 states applied to join a Medicaid model linking selected drug prices to international benchmarks. Forty states and Puerto Rico have signed, while projected $64.3 billion savings remain unverified.
- Author: News Desk
- Tags: Policy

All 50 states, the District of Columbia and Puerto Rico have applied to join a Medicaid drug-pricing model that the Trump administration says could reduce federal and state spending by $64.3 billion over 10 years. The nationwide interest announced Friday gives the five-year experiment an unusually broad reach, but it does not yet mean every state is fully enrolled or that the projected savings have been independently verified.

The Centers for Medicare & Medicaid Services said 40 states and Puerto Rico had signed participation agreements as of September 18; the other 10 states and the District of Columbia have until September 30 to complete agreements. That distinction matters because the [CMS announcement](https://www.cms.gov/newsroom/press-releases/cms-announces-participants-landmark-medicaid-drug-payment-model-bring-down-drug-costs-most?ref=theamericanquorum.com) describes universal applications, while final participation still depends on contracts.

The program, formally called the GENErating cost Reductions fOr U.S. Medicaid Model, or GENEROUS, seeks net prices for selected medicines comparable to prices paid in certain other developed countries. The administration estimates $27.6 billion in state savings and $36.6 billion in federal savings over a decade, according to [Reuters](https://www.reuters.com/world/us/plans-medicaid-most-favored-nation-pricing-some-drugs-all-states-semafor-2026-09-18/?ref=theamericanquorum.com). Those figures remain projections, not observed savings.

## How the pricing model works

GENEROUS uses supplemental rebates rather than setting a public retail price. Participating manufacturers offer states additional rebates intended to reduce Medicaid’s net cost to a most-favored-nation level. States invoice manufacturers, CMS monitors pricing accuracy, and the federal government shares in the rebates through an adjustment to its portion of Medicaid payments.

The arrangement also links price concessions to coverage rules. A CMS [state letter](https://www.cms.gov/priorities/innovation/files/generous-loi-state-medicaid.pdf?ref=theamericanquorum.com) says manufacturers can offer international benchmark prices in exchange for standardized criteria governing which patients receive a covered drug. States may evaluate each manufacturer’s offer separately and can continue negotiating outside the model for medicines that do not receive a GENEROUS price.

That tradeoff is central to the test. Lower net prices could expand access if states use the savings to cover more patients, but standardized criteria could also limit states’ bargaining flexibility or require changes to preferred-drug lists and managed-care contracts. The model is therefore testing both a price mechanism and a new way of coordinating coverage decisions across state programs.

## Why states signed on

Medicaid covers 66.4 million people, according to the program’s May 2026 [enrollment report](https://www.medicaid.gov/medicaid?ref=theamericanquorum.com), and prescription spending is financed jointly by states and the federal government. Even though Medicaid already receives mandatory rebates, drug costs still compete with hospitals, physician services, long-term care and other priorities inside state budgets.

Broad enrollment can also strengthen the model’s bargaining position. A manufacturer deciding whether to participate is being offered a common pathway into every state market rather than a patchwork of separate negotiations. CMS launched GENEROUS in January, and the model runs for five years, giving states time to compare the additional rebates with their existing supplemental agreements and multistate purchasing pools.

The administration has negotiated pricing agreements with more than two dozen manufacturers, including Pfizer, Eli Lilly and Novo Nordisk. The largest clearly identified savings so far have involved obesity medicines, where manufacturers accepted lower government prices alongside broader coverage arrangements. It is not yet public how savings are distributed across other therapeutic classes or how many drugs will produce most of the projected total.

## Savings estimates remain difficult to test

The central limitation is transparency. The administration has not disclosed the full manufacturer contracts, drug-level international benchmarks, expected utilization or baseline net prices needed to reproduce the $64.3 billion estimate. The [Associated Press](https://apnews.com/article/trump-pharmaceuticals-mfn-drug-pricing-35c9cdce7c780d0d06af12f1233a7f32?ref=theamericanquorum.com) reported that outside analysts cannot independently verify the forecast from the information released so far.

Existing Medicaid rebates make that analysis more complicated. A medicine’s list price can be much higher than the confidential net price a state already pays after statutory and supplemental rebates. GENEROUS generates genuine savings only when its internationally linked net price is below that existing amount after administrative costs and changes in use are considered.

Earlier legal analysis of the model’s design also noted that CMS planned to calculate supplemental rebates using a guaranteed net unit price, while leaving important details about the benchmark and allowable manufacturer costs unresolved. That [analysis](https://www.sidley.com/en/insights/newsupdates/2025/11/cms-announces-voluntary-most-favored-nation-pricing-in-medicaid-through-the-generous-model?ref=theamericanquorum.com) underscores why final contracts, drug lists and state-level results will be needed before the headline savings can be treated as established.

## Access and durability are the next tests

Drugmakers argue that importing lower foreign prices could reduce revenue available for research and future investment. The industry’s warning is economically plausible in direction, but its size depends on the drugs included, actual rebate levels and whether manufacturers offset U.S. reductions elsewhere. Conversely, lower Medicaid spending does not automatically translate into lower pharmacy bills for beneficiaries, who generally already have minimal prescription copayments.

The most direct benefit could instead appear in state finances and coverage decisions. If rebates materially reduce net spending, states could expand access to expensive treatments or redirect money within Medicaid. If manufacturers limit participation, utilization rises faster than expected or standardized rules prove difficult to administer, realized savings could fall well below the federal projection.

Friday’s announcement establishes national demand for the experiment, not its outcome. The evidence to watch will be the number of completed state agreements after September 30, the medicines and manufacturers included, independently auditable rebate results and any changes in patient access. Until those data are available, GENEROUS is a nationwide policy test with a large estimated payoff rather than a demonstrated $64.3 billion saving.